The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058.
Gregory M Lucas; Geetha Beauchamp; Apinun Aramrattana; Yiming Shao; Wei Liu; Liping Fu; J Brooks Jackson; David D Celentano; Paul Richardson; David Metzger; et al. (Profiled Authors: David Celentano; J Jackson; Gregory Lucas)
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. email@example.com
The International journal on drug policy 2012;23(2):162-5.
BACKGROUND: Buprenorphine/naloxone (BUP/NX) is not licenced for use in China or Thailand and there was little clinical experience with this drug combination in these countries at the inception of HIV Prevention Trial Network (HPTN) 058, a randomized trial comparing risk reduction counselling combined with either short-term or long-term medication assisted treatment with BUP/NX to prevent HIV infection and death amongst opioid-dependent injectors. METHODS: We conducted a safety phase that included the first 50 subjects enrolled at each of the three initial study sites (N=150). Clinical and laboratory assessments were conducted at baseline and weekly for the first 4 weeks. Changes in laboratory parameters were estimated with random effects models. RESULTS: BUP/NX was well tolerated by study subjects and opioid withdrawal scores decreased substantially during the 3-day induction. Two participants experienced grade 3 clinical adverse events, which were categorized as probably not related to the study drug. Grade 2 or 3 increases in alanine aminotransferase (ALT) occurred in 25 (17%) subjects. The magnitude of ALT increase over 4-week follow-up was strongly associated with baseline ALT elevation. CONCLUSIONS: In Chinese and Thai opioid-dependent injectors, we found BUP/NX to be effective in reducing opioid withdrawal symptoms and safe during short-term use. ALT increases were observed over 4-week-follow-up, which are consistent with reports from Western populations. Long-term safety and efficacy evaluations are indicated.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Frederick L Altice; R Douglas Bruce; Gregory M Lucas; Paula J Lum; P Todd Korthuis; Timothy P Flanigan; Chinazo O Cunningham; Lynn E Sullivan; Pamela Vergara-Rodriguez; David A Fiellin; et al.Journal of acquired immune deficiency syndromes (1999) 2011;56 Suppl 1():S22-32.
P Todd Korthuis; Mary Jo Tozzi; Vijay Nandi; David A Fiellin; Linda Weiss; James E Egan; Michael Botsko; Angela Acosta; Marc N Gourevitch; David Hersh; et al.Journal of acquired immune deficiency syndromes (1999) 2011;56 Suppl 1():S39-45.
E C Strain; J A Harrison; G E BigelowClinical pharmacology and therapeutics 2011;89(3):443-9.
Appears in this Publication
Author of this Publication